-
-
-
-
-
-
-
Adicet Bio doses first patient in rheumatoid arthritis trial
-
-
-
-
-
-
-
Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
-
-
-
-
-
-
-
Adicet Bio (ACET) Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis
-
-
-
-
-
-
-
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
-
-
-
-
-
-
-
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
-
-
-
-
-
-
-
Adicet Bio (ACET): ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue
-
-
-
-
-
-
-
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

